TY - JOUR
T1 - Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer
T2 - A preliminary study
AU - Lopez-Berestein, Gabriel
AU - Fainstein, Victor
AU - Hopfer, Roy
AU - Mehta, Kapil
AU - Sullivan, Margaret P.
AU - Keating, Michael
AU - Rosenblum, Michael G.
AU - Mehta, Reeta
AU - Luna, Mario
AU - Hersh, Evan M.
AU - Reuben, James
AU - Juliano, Rudolph L.
AU - Bodey, Gerald P.
N1 - Funding Information:
This work was supported in part by a grant from the Kleberg Foundation, and by a grant from the U.T. M.D. Anderson President's Development Funds to Dr. Lopez-Berestein. Dr. LopezBerestein is a Fellow of the Leukemia Society of America.
PY - 1985
Y1 - 1985
N2 - Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed. All patients had biopsy findings or cultural evidence of the progression of their fungal infection while being treated with conventional amphotericin B. Doses of 0.8-1.0 mg/kg of L-AmpB were administered intravenously every 24-72 hr. Three patients had a complete remission, five had a partial remission, and four showed no improvements. A total of 161 doses of L-AmpB were administered. Fever and chills occurred on seven occasions. No hematologic or blood chemistry abnormalities related to L-AmpB treatment were observed.
AB - Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed. All patients had biopsy findings or cultural evidence of the progression of their fungal infection while being treated with conventional amphotericin B. Doses of 0.8-1.0 mg/kg of L-AmpB were administered intravenously every 24-72 hr. Three patients had a complete remission, five had a partial remission, and four showed no improvements. A total of 161 doses of L-AmpB were administered. Fever and chills occurred on seven occasions. No hematologic or blood chemistry abnormalities related to L-AmpB treatment were observed.
UR - http://www.scopus.com/inward/record.url?scp=0021958862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021958862&partnerID=8YFLogxK
U2 - 10.1093/infdis/151.4.704
DO - 10.1093/infdis/151.4.704
M3 - Article
C2 - 3973417
AN - SCOPUS:0021958862
SN - 0022-1899
VL - 151
SP - 704
EP - 710
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -